Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
93.5% of the p53 immunopositive carcinomas were ER-negative, and in 95.7% of this subclass of patients no PgR could be detected.
|
11299837 |
2001 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Carcinomas associated with Recurrence Score ≥18 showed lower progesterone receptor immunoreactivity, increased stromal cellularity and presence of inflammatory cells associated with the tumor.
|
22173289 |
2012 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Carcinomas with polysomy 17 were associated with adverse histological indicators including high histological grade, high nuclear grade, poor Nottingham Prognostic Index, advanced local tumour extent and progesterone receptor negativity.
|
23908451 |
2013 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Carcinomas in the under 30 years age group had a lower incidence of oestrogen and progesterone receptor positivity.
|
8956795 |
1996 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A good pathological response, defined as a pathological complete response or residual isolated invasive tumor cells, was found significantly more frequently for estrogen (ER) and progesterone receptor (PR) negative breast carcinomas compared to ER and PR positive and ER or PR positive carcinomas, respectively (43.5 vs. 37.5 and 10.3 %, p = 0.006), and was significantly associated with high tumor grade (G3) (p = 0.002).
|
22903472 |
2012 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A higher percentage of comedo-invasive carcinomas demonstrated aneuploidy 71%; p = 0.0158), elevated levels of S-phase fraction (75%; p = 0.0016) and Ki-67 staining (55%; p = 0.0512), overexpression of HER-2/neu oncogene (47%; p = 0.0011), and were ER negative (35%; p = 0.0148), PR negative (47%; p = 0.0073) when compared to noncomedo-invasive carcinomas.
|
7496840 |
1995 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although a combination of these 3 markers is slightly superior to the traditional histological markers, a prognostic model including stage, PR expression, and LVSI is the most promising model in the identification of high risk carcinomas.
|
29324536 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Among patients with LM332 β3-expressing and ER/PgR-negative carcinomas, 10-year survival was significantly reduced (P < .0450).
|
30125583 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Densely punctate/coarsely granular nuclear reactivity was significantly associated with high tumour grade (p<0.005, p=0.033 in invasive carcinomas and DCIS respectively), negative estrogen receptor status (p=0.008, p=0.038 in overall cohort and invasive carcinomas, respectively), negative progesterone receptor status (p=0.003, p=0.013 in overall cohort and invasive carcinomas, respectively), <i>HER2</i> amplification (overall cohort p=0.034) and non-luminal intrinsic subtype (p=0.018, p=0.038 in overall cohort and invasive carcinomas, respectively).
|
29137369 |
2017 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Eighteen of 58 (31%) carcinomas were estrogen receptor positive and 22 (38%) were positive for progesterone receptor.
|
7919121 |
1994 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Forty-two pure salivary duct carcinomas, 35 of which contained an in-situ component as defined by histological review and/or immunohistochemical analysis, were stained with antibodies for oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6.
|
22882517 |
2012 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we evaluate telomere lengths within 48 primary ILCs with complete characterization of estrogen receptor (ER), progesterone receptor (PR), and Her2 status, including 32 luminal/Her2- (ER+/PR+/Her2-), 8 luminal/Her2+ (ER+/PR+/Her2+), 3 Her2+ (ER-/PR-/Her2+), and 5 triple-negative (ER-/PR-/Her2-) carcinomas.
|
26092192 |
2015 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
High MYC amplification was seen in grade III carcinomas (MYC: CEP8 = 2.42), pre-menopausal women (MYC: CEP8 = 2.49), PR-negative status (MYC: CEP8 = 2.42), and ER-positive status (MYC: CEP8 = 2.4).
|
29523126 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histologic slides were reviewed by 2 pathologists, and immunohistochemical staining for p53, ki67, estrogen receptor, and progesterone receptor was performed on carcinomas and dysplastic and benign tubal epithelia.
|
16319259 |
2005 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, there was a weak but significant negative correlation between hTERT expression and progesterone receptor (PR) status (p = 0.04) in tumours. hTERT mRNA expression was also significantly higher in carcinomas (median = 2.61 x 10(6)) than in fibroadenomas (median = 424).We conclude that hTERT mRNA expression is significantly higher in human breast cancer than in non-cancerous breast tissue suggesting that hTERT has a potential role in breast cancer diagnosis.
|
12602927 |
2003 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In carcinomas GH mRNA was also found in progesterone receptor-negative tissue samples, indicating that after malignant transformation GH gene expression may become progestin independent.
|
7738169 |
1995 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Infiltrating lobular carcinoma had a higher ER positivity between groups (85.7%), whereas noninvasive carcinomas had a higher PR positivity (67%).
|
26266392 |
2015 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mean ER and PR levels were highest in hyperplastic lesions, especially those with atypical features, whereas carcinomas of all grades had significantly lower values.
|
8491764 |
1993 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, ER and PR were expressed in 42 (66%) and 42 (66%) carcinomas, respectively, and in neither of the 2 phyllode tumors.
|
16211220 |
2005 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nuclear expression of estrogen and progesterone receptors was increased in both indolent and aggressive neoplasms, but was without sex- or age-related differences; however, whereas progesterone receptor expression was diffuse and strong in clinically indolent carcinomas, its expression was diminished in aggressive neoplasms.
|
21358618 |
2011 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile.
|
20208479 |
2010 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PPARgamma immunoreactivity was detected in 42% of carcinomas, and was significantly associated with the status of estrogen receptor (ER) alpha, ERbeta, progesterone receptor, retinoic X receptors, p21 or p27, and negatively correlated with histological grade or cyclooxygenase-2 status.
|
16601291 |
2006 |
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Quantitative real-time polymerase chain reaction demonstrated that ER alpha, ER beta and PR were statistically elevated by 3-, 4- and 8-fold in carcinomas compared with normal mammary glands.
|
15637090 |
2005 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quantitatively increased nm23-H1 immunopositive staining was more frequently observed in special histologic types of infiltrating cancers, in high nuclear grade tumors, as well as in carcinomas with high PgR levels (p = 0.05).
|
10403901 |
1999 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Subsequent comparison between 20 carcinomas using AFM220xe5, with and without LOH in terms of pathological parameters showed significant associations with differences in age (P = 0.04) ER (P = 0.05) Ki-67 (P = 0.04) and PR (P = 0.01) a trend toward significance was found for tumor size (P = 0.06) and histological grade III (P = 0.06).
|
15183540 |
2004 |